Company: PAYC
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001193125-25-072358
Chunk: 6

Company: Paycom Software, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 6
---
 beverage company                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                         |     |                                                                              | ›                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Group Controller and Treasury (1994-2002)                                                                                                                                                            |
|                                                                                                                                                                                                                                                         |     |                                                                              | Other experience: Held various audit and financial roles at Bristol-Myers Squibb and Arthur Andersen & Company                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                         |     |                                                                              | OTHER BOARD SERVICE                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                         |     |                                                                              | ANYWHERE REAL ESTATE INC. (NYSE: HOUS) (since 2021), chair of audit committee                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                         |     |                                                                              | NEOGENOMICS LABORATORIES, INC. (NASDAQ: NEO) (since 2024), audit and finance committee and nominating and corporate governance committee                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                         |     |                                                                              | MERIDIAN BIOSCIENCE, INC. (formerly NASDAQ: VIVO) (2018-2023)                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                      |

13

<div align='center'>14</div>

| 87.5% Independence   7 Independent 1 Non-Independent |     | 60% Board Leadership Diversity   60% of Board leadership roles held by diverse directors based on gender or race/ethnicity |     | 5 years Average Tenure of Independent Directors   Average tenure of all directors is 7.8 years |     | Tenure   50% of directors: 0-4 years 25% of directors: 5-9 years 25% of directors: 10+ years |

Board refreshment is key to ensure our Board composition reflects the optimal blend of experience and skills to conduct oversight over the Company’s strategic objectives. The Board strives to maintain a balance of tenured directors, who bring valuable experience and institutional knowledge, as well as newer directors, who bring fresh perspectives and skills. Board Structure

| Our Corporate Governance Guidelines provide that both independent and management directors are eligible for appointment as Chairman of the Board of Directors. We believe it is important that the Board of Directors retain flexibility to determine whether these roles should be separate or combined based upon all relevant facts and circumstances at a given point in time. Our Corporate